Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder

被引:16
|
作者
Belgaied, Wael [1 ]
Sarnp, Jennifer [2 ]
Vimont, Alexandre [1 ]
Remuzat, Cecile [1 ]
Aballea, Samuel [1 ]
El Hammi, Emna [1 ]
Kooli, Amna [1 ]
Toumi, Mondher [1 ,3 ]
Akhras, Kasem [2 ]
机构
[1] Creativ Ceutical, Deerfield, IL USA
[2] Takeda Pharmaceut Int Inc, Deerfield, IL USA
[3] Univ Lyon 1, UFR Odontol, F-69372 Lyon, France
关键词
Cognitive dysfunction; Schizophrenia; Major depressive disorder; Bipolar disorder; Cognitive instruments; Survey; NEUROCOGNITIVE IMPAIRMENT; BATTERY;
D O I
10.1016/j.euroneuro.2013.11.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As more evidence points to the association of cognitive dysfunction with mental health disorders, the assessment of cognitive function in routine clinical care of these disorders is increasingly important. Despite this, it remains unknown how cognitive function is measured in routine clinical practice. The objective of this study was to assess psychiatrists awareness of cognitive dysfunction in mental health disorders and their methods of cognitive assessment. An online survey was disseminated to psychiatrists in Europe, Asia, Australia and the United States. The survey asked about their perceptions of cognitive dysfunction in several mental health disorders, knowledge of cognitive assessment, method of cognitive assessment, and instruments used to measure cognitive function. Among the 61 respondents, most perceived that schizophrenia was associated with the greatest cognitive dysfunction. Many were unaware whether guidelines were available on cognitive assessment. In schizophrenia, 59% of psychiatrists reportedly used cognitive instruments, while the remainder relied solely on patient history interviews. The use of instruments to assess cognition in major depressive disorder (MDD) and bipolar disorder (BPD) was lower, 38% and 37% respectively. Of the reported instruments used, only a few were actually appropriate for use in the diseases of interest (12% in schizophrenia, 3% in MDD and 0% in BPD). Other instruments reported were clinical measures that did not assess cognition. These findings reveal some inconsistencies in psychiatrists' routine clinical evaluation of cognitive function. There appeared to be low use of true cognitive assessment instruments in clinical practice and confusion regarding what constituted a cognitive assessment instrument. (C) 2013 Elsevier B.V. and ECNP. All rights reserved.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 50 条
  • [31] Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function
    Yu, Hua
    Ni, Peiyan
    Zhao, Liansheng
    Tian, Yang
    Li, Mingli
    Li, Xiaojing
    Wei, Wei
    Wei, Jinxue
    Deng, Wei
    Du, Xiangdong
    Wang, Qiang
    Guo, Wanjun
    Ma, Xiaohong
    Coid, Jeremy
    Li, Tao
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [32] Key subphenotypes of bipolar disorder are differentially associated with polygenic liabilities for bipolar disorder, schizophrenia, and major depressive disorder
    Song, Jie
    Jonsson, Lina
    Lu, Yi
    Bergen, Sarah E.
    Karlsson, Robert
    Smedler, Erik
    Gordon-Smith, Katherine
    Jones, Ian
    Jones, Lisa
    Craddock, Nick
    Sullivan, Patrick F.
    Lichtenstein, Paul
    Di Florio, Arianna
    Landen, Mikael
    MOLECULAR PSYCHIATRY, 2024, 29 (7) : 1941 - 1950
  • [33] Integrating proteomic and clinical data to discriminate major psychiatric disorders: Applications for major depressive disorder, bipolar disorder, and schizophrenia
    Shin, Dongyoon
    Rhee, Sang Jin
    Shin, Daun
    Joo, Eun-Jeong
    Jung, Hee Yeon
    Roh, Sungwon
    Lee, Sang-Hyuk
    Kim, Hyeyoung
    Bang, Minji
    Lee, Kyu Young
    Kim, Se Hyun
    Lee, Jihyeon
    Kim, Yoseop
    Yeo, Injoon
    Kim, Yeongshin
    Kim, Jaenyeon
    Kwon, Jun Soo
    Ha, Kyooseob
    Ahn, Yong Min
    Kim, Youngsoo
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (06):
  • [34] Cognitive functioning during depressive and manic episodes in bipolar disorder
    Ioannidi, N.
    Konstantakopoulos, G.
    Ploumpidis, D.
    Sakkas, D.
    Papadimitriou, G. N.
    Oulis, P.
    BIPOLAR DISORDERS, 2012, 14 : 85 - 85
  • [35] Association between cognitive symptoms and everyday functioning in patients with major depressive disorder (MDD) in routine clinical practice in Greece
    Galanopoulos, A.
    Roukas, D.
    Karaiskos, D.
    Argyropoulos, I.
    Spyropoulou, A.
    Vassilopoulou, P.
    Fotiadis, P.
    Papalexi, E.
    EUROPEAN PSYCHIATRY, 2019, 56 : S88 - S88
  • [36] Cognitive functioning in patients with schizophrenia and bipolar disorder: A quantitative review
    Krabbendam, L
    Arts, B
    van Os, J
    Aleman, A
    SCHIZOPHRENIA RESEARCH, 2005, 80 (2-3) : 137 - 149
  • [37] Cognitive functioning in first-episode schizophrenia and bipolar disorder
    Murphy, PT
    Burke, T
    McTigue, O
    Kamali, M
    Clarke, M
    Larkin, C
    O'Callaghan, E
    Lane, A
    SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 267 - 268
  • [38] Shared reduction of oscillatory natural frequencies in bipolar disorder, major depressive disorder and schizophrenia
    Canali, P.
    Sarasso, S.
    Rosanova, M.
    Sferrazza-Papa, G.
    Smeraldi, E.
    Benedetti, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S193 - S193
  • [39] Identifying plasma metabolic characteristics of major depressive disorder, bipolar disorder, and schizophrenia in adolescents
    Yin, Bangmin
    Cai, Yuping
    Teng, Teng
    Wang, Xiaolin
    Liu, Xueer
    Li, Xuemei
    Wang, Jie
    Wu, Hongyan
    He, Yuqian
    Ren, Fandong
    Kou, Tianzhang
    Zhu, Zheng-Jiang
    Zhou, Xinyu
    TRANSLATIONAL PSYCHIATRY, 2024, 14 (01)
  • [40] Common and Specific Functional Activity Features in Schizophrenia, Major Depressive Disorder, and Bipolar Disorder
    Yang, Yongfeng
    Liu, Shu
    Jiang, Xiaoyan
    Yu, Hongyan
    Ding, Shuang
    Lu, Yanli
    Li, Wenqiang
    Zhang, Hongxing
    Liu, Bing
    Cui, Yue
    Fan, Lingzhong
    Jiang, Tianzi
    Lv, Luxian
    FRONTIERS IN PSYCHIATRY, 2019, 10